First Patient Dosed in Phase 1 Trial of SY-5609 for OC, Other Solid Tumors, Syros Announces
News
Syros Pharmaceuticals announced the dosing of the first patient in its Phase 1 trial of SY-5609, an investigational oral medication for ovarian cancer and other types of solid tumors. The ... Read more